<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Noufou Ouédraogo</style></author><author><style face="normal" font="default" size="100%">W. Leila Marie Esther Belem-Kabré</style></author><author><style face="normal" font="default" size="100%">A.M. Emmanuel Thiombiano</style></author><author><style face="normal" font="default" size="100%">Tata Kadiatou Traoré</style></author><author><style face="normal" font="default" size="100%">Lazare Belemnaba</style></author><author><style face="normal" font="default" size="100%">Moussa Ouédraogo</style></author><author><style face="normal" font="default" size="100%">Innocent Pierre Guissou</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Anti-inflammatory Potential of Glycoside Flavonoids from Pterocarpus erinaceus Poir. (Fabaceae) Leaves</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antioxidant</style></keyword><keyword><style  face="normal" font="default" size="100%">Compounds</style></keyword><keyword><style  face="normal" font="default" size="100%">Enzymes</style></keyword><keyword><style  face="normal" font="default" size="100%">Medicinal plant.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">593-598</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Chronic diseases have become one of the leading causes of death worldwide in recent years. Despite tremendous advances in the treatments of diseases, several concerns remain. Those with inflammatory components are alternatively treated or completed in Burkina Faso with medicinal plants. The present study was designed to identify and evaluate the anti-inflammatory potential of glycoside flavonoids from &lt;em&gt;Pterocarpus Erinaceus &lt;/em&gt;leaves. &lt;strong&gt;Methods: &lt;/strong&gt;The ﬂavonoids contained in &lt;em&gt;Pterocarpus Erinaceus&lt;/em&gt; aerial parts were extracted, identified, and characterized. Sequential soxhlet extraction was subjected to preliminary phytochemical screening, and characterization of isolated ﬂavonoid was done by U.V., I.R., 1H &amp;amp; 13C N.M.R. and MS. Subsequently, isolates were tested&lt;em&gt; in vitro&lt;/em&gt; for their antiinflammatory potential as well as their antioxidant capacities. &lt;strong&gt;Results: &lt;/strong&gt;Five compounds were determined as corresponding to 3’,4’,5,7-tetrahydroxy flavone (luteolin); quercetin-3-O- sophoroside; quercetin- 3-0-β-glucose (isoquercitrin); Kaempferol-3-O-sophoroside and 3,3’,4’,5,7-pentahydroxyflavone-3- rhamnoglucoside (rutin). Concentrations of quercetin-3-O- sophoroside and quercetin-3-0-β-glucose that inhibit 50% of pro-inflammatory enzymes’ activities were expressed in μg/mL. They were respectively 18.07 ± 0.78 and 32.27 ± 2.02 for xanthine oxidase, 1.12 ± 0.018 and 11.53 ± 0.52 for lipoxygenase, 26.91 ± 0.34 and 19.54 ± 0.25 for acetylcholinesterase. Prevention of the degradation of deoxyribose test gave respectively 19.32 ± 1.08 μg/mL and 26.21 ± 2.25 μg/mL for quercetin-3-O- sophoroside and quercetin-3-O- β-glucose while the anti-DPPH free radical potential was 3.41 ± 0.82 and 2.90 ± 0.18 μg/ mL. &lt;strong&gt;Conclusion: &lt;/strong&gt;These results may justify the traditional uses of P. erinaceus in treating diseases with an inflammatory component.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">593</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Noufou Ouédraogo&lt;sup&gt;1,3&lt;/sup&gt;, W. Leila Marie Esther Belem-Kabré&lt;sup&gt;1,2,&lt;/sup&gt;*, A.M. Emmanuel Thiombiano&lt;sup&gt;2&lt;/sup&gt;, Tata Kadiatou Traoré&lt;sup&gt;1,3&lt;/sup&gt;, Lazare Belemnaba&lt;sup&gt;1&lt;/sup&gt;, Moussa Ouédraogo&lt;sup&gt;3&lt;/sup&gt;, Innocent Pierre Guissou&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Département Médecine et Pharmacopée Traditionnelles – Pharmacie (MEPHATRA-PH), Institut de Recherche en Sciences de la Santé (IRSS/CNRST), 03 BP 7047 Ouagadougou 03, BURKINA FASO.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Laboratoire de Biochimie et Chimie Appliquée (LABIOCA), Ecole Doctorale Sciences et Technologie, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03, BURKINA FASO.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Laboratoire de développement du médicament (LADME) / CEA-CFOREM, Ecole Doctorale Sciences de la Santé, Université Joseph KI-ZERBO 03 BP 7021 Ouagadougou 03, BURKINA FASO.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tsolanku Sidney Maliehe</style></author><author><style face="normal" font="default" size="100%">Phakamani Hopewell Tsilo</style></author><author><style face="normal" font="default" size="100%">Jabulani Siyabonga Shandu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Computational Evaluation of ADMET Properties and Bioactive Score of Compounds from Encephalartos ferox</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bioactive score</style></keyword><keyword><style  face="normal" font="default" size="100%">Compounds</style></keyword><keyword><style  face="normal" font="default" size="100%">Pharmacokinetic; Drug-likeness</style></keyword><keyword><style  face="normal" font="default" size="100%">Toxicity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">September 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1357-1362</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Plant based products are recognised as sources of drugs for treatment of diseases. &lt;strong&gt;Objective:&lt;/strong&gt; The study aimed at predicting the physicochemical, pharmacokinetics, drug-likeness and toxicity of the compounds identified from the methanolic &lt;em&gt;Encephalartos ferox&lt;/em&gt; fruit extract. &lt;strong&gt;Methods: &lt;/strong&gt;The physicochemical, pharmacokinetics properties and bioactive scores of the compounds were predicted using SwissADME and Molinspiration computational tools. Drug-likeness of the compounds was evaluated based on the Lipinski rule of five (Ro5).&lt;em&gt; In silico&lt;/em&gt; mutagenicity, carcinogenicity and inhibition of human ether-a-go-go-related (hERG) gene were also investigated using PreADMET web tool. &lt;strong&gt;Results: &lt;/strong&gt;The physicochemical properties showed the compounds, except 9-Octadecenoic acid, 1, 2, 3-propanetriyl ester to adhere to Ro5. The evaluation of their inhibitory effects profile in several cytochrome P450 isoforms indicate that all the compounds are not the inhibitors of CYP2C19 and CYP3A4 whereas some inhibited CYP1A2, CYP2C9 and CYP2D6. The drug-likeness evaluation employed Ro5 as a filter and all compounds complied with it except for 9-Octadecenoic acid, 1, 2, 3-propanetriyl ester. About 50% of the tested compound were found to be safe as they did not exhibit antimutagenic and carcinogenic effects. Moreover, the risk of inhibition of hERG gene revealed to be low to medium risk depending on the compound. &lt;strong&gt;Conclusion: &lt;/strong&gt;The calculated physicochemical and pharmacokinetic properties suggest that most of the compounds are safe and have promising oral bioavailability.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1357</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Tsolanku Sidney Maliehe&lt;sup&gt;1,&lt;/sup&gt;*, Phakamani Hopewell Tsilo&lt;sup&gt;1&lt;/sup&gt;, Jabulani Siyabonga Shandu&lt;sup&gt;1 &lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Biochemistry and Microbiology, Faculty of Science and Agriculture, University of Zululand, KwaDlangezwa 3886, SOUTH AFRICA.&lt;/p&gt;
</style></auth-address></record></records></xml>